Charles Schwab Investment Management Inc. Acquires 17,372 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Charles Schwab Investment Management Inc. boosted its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 8.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 233,717 shares of the company’s stock after acquiring an additional 17,372 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.41% of Ginkgo Bioworks worth $2,295,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Forbes J M & Co. LLP increased its position in Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after acquiring an additional 576,732 shares during the period. Erste Asset Management GmbH acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at $4,075,000. Jacobs Levy Equity Management Inc. bought a new position in Ginkgo Bioworks in the 3rd quarter valued at about $2,282,000. BNP Paribas Financial Markets bought a new position in Ginkgo Bioworks during the 3rd quarter valued at $1,287,000. Finally, PDT Partners LLC bought a new stake in Ginkgo Bioworks in the 3rd quarter worth about $1,199,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

Shares of NYSE:DNA opened at $6.16 on Friday. The company has a market capitalization of $357.26 million, a PE ratio of -0.47 and a beta of 1.23. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.26 and a 1 year high of $47.60. The business has a fifty day moving average price of $10.36 and a two-hundred day moving average price of $9.22.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.